FDA rejection to delay Lebrikizumab chances to enter atopic dermatitis market: GlobalData
GlobalData currently expects Lilly to resubmit lebrikizumab’s BLA in Q4 2023
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.